序号股票简称PE(TTM)PE(静)市净率总市值(元)7诺思格30.4831.132.3443.65亿行业平均 39.5845.743.43155.97亿行业中值40.6052.662.7056.52亿1药明康德16.8719.963.031886.47亿2康龙化成 22.1623.082.95413.96亿3诺泰生物24.1229.264.31118.34亿4普蕊斯25.9622.232.0023.66亿5诺禾致源 27.7928.722.2356.52亿6凯莱英30.0031.411.73298.03亿8爱尔眼科31.1532.475.291154.48亿9华康洁净 35.1736.811.4224.59亿10通策医疗35.5236.294.32181.96亿11昭衍新药36.72192.041.75142.25亿12华厦眼科 37.7437.192.70159.43亿 来源：金融界 资金流向方面，6月26日，诺思格主力资金净流出311.84万元，近5日总体呈流出状态，5日共流出 1968.35万元。 诺思格(北京)医药科技股份有限公司的主营业务是为全球的医药企业和科研机构提供综合的药物临床研 发全流程一 ...

截至2025年一季报，共有12家机构持仓诺思格，其中基金7家、其他5家，合计持股数3279.94万股，持 股市值16.85亿元。 诺思格(北京)医药科技股份有限公司的主营业务是为全球的医药企业和科研机构提供综合的药物临床研 发全流程一体化服务。公司的主要产品是临床试验运营服务、临床试验现场管理服务、数据管理与统计 分析服务、生物样本检测服务、临床试验咨询服务、临床药理学服务。 最新一期业绩显示，2025年一季报，公司实现营业收入1.73亿元，同比-2.53%；净利润2607.37万元，同 比13.12%，销售毛利率36.53%。 6月5日，诺思格今日收盘50.65元，下跌2.61%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到34.15倍，总市值48.92亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)24诺思格34.1534.892.6348.92亿行业平均 40.8246.973.46158.62亿行业中值45.9353.092.7358.93亿1润达医疗-291.25192.732.51106.54亿2何氏眼 科-154.63-134.561.9336.87亿3*ST生物- ...

Core Viewpoint - The company has decided to terminate the "Data Science Center Project" and permanently supplement the remaining raised funds into working capital due to changes in market conditions and its operational strategy [4][6][8]. Fundraising Overview - The company raised a total of RMB 1,183.2 million from its initial public offering, with a net amount of RMB 1,087.6 million after deducting issuance costs [1]. - As of April 30, 2025, the company has used RMB 578.5 million of the raised funds, leaving a balance of RMB 558.9 million [2]. Investment Project Status - The total investment for committed projects is RMB 610 million, with RMB 298.5 million already invested [2]. - The company has also allocated RMB 477.6 million for projects funded by excess raised funds, with RMB 280 million already utilized [2]. Termination of Investment Projects - The "Data Science Center Project" was intended to enhance the company's data management and statistical analysis capabilities but has been terminated due to macroeconomic factors and market demand changes [5][6]. - The remaining funds from this project, amounting to RMB 177.7 million, will be permanently added to working capital [6]. Impact on Daily Operations - The termination of the project is expected to have no adverse effects on the company's existing operations and is seen as a strategic decision to optimize fund usage [6][8]. - The decision aligns with the company's goal to improve the efficiency of fund utilization and meet daily operational funding needs [6][8]. Approval Process - The board of directors has approved the termination of the project and the reallocation of funds, which will be submitted for shareholder approval [7][8]. Sponsor's Review Opinion - The sponsor believes that the decision to terminate the project and reallocate funds is in line with the company's operational needs and will enhance the economic benefits of the raised funds [8][9].

从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均38.49倍，行业中值39.26倍，诺思格排名 第23位。 截至2025年一季报，共有12家机构持仓诺思格，其中基金7家、其他5家，合计持股数3279.94万股，持 股市值16.85亿元。 5月20日，诺思格今日收盘44.6元，上涨1.71%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到30.07倍，总市值43.08亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.73亿元，同比-2.53%；净利润2607.37万元，同 比13.12%，销售毛利率36.53%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)23诺思格30.0730.722.3143.08亿行业平均 38.4944.343.45153.98亿行业中值39.2651.172.7152.70亿1润达医疗-295.54195.572.55108.11亿2何氏眼 科-141.11-122.801.7633.64亿3*ST生物-124.18-120.7310.2023.96亿4诚达药业-70.53-120.841.5933.96亿5普 瑞眼科-68.23-61. ...

诺思格(北京)医药科技股份有限公司的主营业务是为全球的医药企业和科研机构提供综合的药物临床研 发全流程一体化服务。公司的主要产品是临床试验运营服务、临床试验现场管理服务、数据管理与统计 分析服务、生物样本检测服务、临床试验咨询服务、临床药理学服务。 最新一期业绩显示，2025年一季报，公司实现营业收入1.73亿元，同比-2.53%；净利润2607.37万元，同 比13.12%，销售毛利率36.53%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)23诺思格30.0830.732.3143.09亿行业平均 38.1544.203.39150.89亿行业中值38.4849.482.6651.49亿1润达医疗-308.74204.312.66112.94亿2何氏眼 科-135.81-118.181.6932.38亿3*ST生物-118.02-114.749.7022.77亿4普瑞眼科-70.21-63.073.0164.25亿5诚达 药业-68.67-117.641.5433.06亿6皓宸医疗-50.77-61.076.0223.02亿7国际医学-45.64-45.903.27116.64亿8创新 医疗- ...

Company Overview - Norsg achieved a closing price of 44.77 yuan, down 20.00%, with a rolling PE ratio of 30.84 times and a total market value of 4.324 billion yuan [1] - The company operates in the medical services industry, which has an average PE ratio of 45.72 times and a median of 41.83 times, placing Norsg at the 25th position in the industry ranking [1] Shareholding Structure - As of the 2024 annual report, 112 institutions hold shares in Norsg, including 106 funds and 6 other entities, with a total shareholding of 43.1268 million shares valued at 2.156 billion yuan [1] Business Operations - Norsg specializes in providing comprehensive drug clinical research and development services for global pharmaceutical companies and research institutions, including clinical trial operation services, site management services, data management and statistical analysis services, biological sample testing services, clinical trial consulting services, and clinical pharmacology services [1] Financial Performance - For the 2024 annual report, Norsg reported an operating revenue of 744 million yuan, a year-on-year increase of 3.14%, and a net profit of 140 million yuan, reflecting a year-on-year decrease of 13.73%, with a sales gross margin of 37.09% [1]

4月1日，诺思格今日收盘53.0元，上涨3.15%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到36.51倍，总市值51.19亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均52.86倍，行业中值49.90倍，诺思格排名 第26位。 股东方面，截至2025年2月28日，诺思格股东户数5105户，较上次减少336户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)26诺思格36.5136.512.7951.19亿行业平均 52.8647.733.76166.77亿行业中值49.9041.242.8051.60亿1普瑞眼科-185.3323.162.8062.06亿2何氏眼 科-165.9550.881.6732.33亿3迪安诊断-106.4132.041.4098.50亿4光正眼科-95.73227.447.7121.05亿5创新医 疗-92.46-129.222.4044.30亿6南华生物-89.74-118.0813.3833.27亿7国际医学-35.28-34.303.46126.36亿8嘉和 美康-30.45- ...